ClinicalTrials.gg
RecruitingNCT06240546Updated Mar 15, 2024

First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors.

A Phase 1 interventional study of LPM6690176 in Advanced Solid Tumor, sponsored by Luye Pharma Group Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-03-15.

Sponsored by Luye Pharma Group Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
102
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is a phase 1, first-in-human, open-label, dose-escalation and dose-expansion study designed to evaluate the safety and tolerability, pharmacokinetics characteristics and preliminary anti-tumor activity of LPM6690176 capsules in patients with advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Luye Pharma Group Ltd. is the lead sponsor of 74 studies on the registry; 15 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide a signed ;
  2. Age 18 \~ 75 years, male or female;
  3. Patients with or cytologically confirmed advanced or unresectable solid tumors, who failed or intolerant to standard anti-tumor therapy or lack of standard therapy;
  4. According to 1.1 criteria,

    • Dose escalation phase: patients with at least one non-;
    • Dose expansion phase: patients with at least one measurable lesion;
  5. (ECOG) score of 0 or 1;
  6. ≥ 3 months;
  7. Adequate bone marrow, liver, kidney, metabolism and coagulation function (blood transfusion, colony stimulating factors, albumin, and blood products are not allowed to use within 14 days before enrollment);
  8. Negative pregnancy test within 7 days before first dose of study drug treatment in women of childbearing age. Female patients with were to use effective during and for 6 months after the first dose of study drug treatment. Male patients (female partners with childbearing potential) should take effective contraceptive measures during study drug treatment and until 4 months after last dose of study drug administration.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have not recovered from AEs caused by previous anti-tumor therapy to ≤ Grade 1 (assessed according to 5.0 criteria, excluding alopecia and ≤ Grade 2 peripheral sensory neuropathy);
  2. Pleural effusion, pericardial effusion, or ascites requiring medical intervention or frequent drainage within 1 month before signed decided by the investigator;
  3. Symptomatic , history of spinal cord compression or ;
  4. Concomitant Diseases:

    • Any of the following diseases within 6 months before the first dose of study treatment: myocardial infarction, unstable angina, coronary artery/peripheral artery bypass grafting, symptomatic congestive heart failure, cerebrovascular accident or , pulmonary embolism, deep vein thrombosis, and serious arrhythmia requiring treatment;
    • Patients who require long-term anticoagulant therapy or anti- therapy or require long-term use of non-steroidal anti-inflammatory drugs;
    • Patients with uncontrolled hypertension, hypertensive crisis or history of hypertensive encephalopathy;
    • Patients with increased risk of gastrointestinal ulcer or gastrointestinal bleeding tendency or gastrointestinal perforation tendency;
    • Patients with known active colitis within 8 weeks prior to screening, or diarrhea ≥4 times in 24 hours;
    • Active infection requiring systemic antibacterial, antifungal, or antiviral therapy within 2 weeks before the first dose of study drug treatment;
    • (+) and HBV DNA≥ 1×103 or (+) or (+);
    • Patients who have undergone major surgical procedures 4 weeks before the first dose of study drug treatment, or have severe injury, or requiring elective major surgery during the study, or have unhealed wounds, ulcers or fractures;
    • Exclusion criterion specific to dose expansion phase: patients who have any within 5 years before the first dose of study treatment except for the specific cancer under investigation in this study (cured carcinoma in situ of the cervix, basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of breast ductal are eligible).
  5. Prior Medications:

    • Patients who received anti-tumor therapy within 4 weeks before the first dose of study drug treatment;
    • Received LPM6690176 capsules or other PLK-1 inhibitors therapy before enrollment;
    • Received within 4 weeks before signed informed consent;
    • Use of strong inducers or strong inhibitors of within 2 weeks or 5 half-lives of the medication before the first dose of study drug treatment;
    • Use of medications mainly metabolized by CYP2B6 within 2 weeks or 5 half-lives (which takes longer time) of the medication before the first dose of study drug treatment;
  6. Patients who may receive other systemic anti-tumor therapy or local radical therapy of target lesions/non-target lesions during the study;
  7. History of drug abuse, drug addiction, or alcoholism;
  8. Known to any component of the study drug;
  9. Patients who participated in other clinical trials and received treatment within 1 month;
  10. Pregnant or lactating women;
  11. Other conditions that may elevate the risk of the patient or interfere the study results decided by the investigator.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    2 mg/m2

    LPM6690176 capsules administered 2 mg/m2 on day 1-5 (qd) every two weeks.

    Drug: LPM6690176

  • Experimental
    4 mg/m2

    LPM6690176 capsules administered 4 mg/m2 on day 1-5 (qd) every two weeks.

    Drug: LPM6690176

  • Experimental
    8 mg/m2

    LPM6690176 capsules administered 8 mg/m2 on day 1-5 (qd) every two weeks.

    Drug: LPM6690176

  • Experimental
    16 mg/m2

    LPM6690176 capsules administered 16 mg/m2 on day 1-5 (qd) every two weeks.

    Drug: LPM6690176

  • Experimental
    24 mg/m2

    LPM6690176 capsules administered 24 mg/m2 on day 1-5 (qd) every two weeks.

    Drug: LPM6690176

  • Experimental
    36 mg/m2

    LPM6690176 capsules administered 36 mg/m2 on day 1-5 (qd) every two weeks.

    Drug: LPM6690176

  • Experimental
    48 mg/m2

    LPM6690176 capsules administered 48 mg/m2 on day 1-5 (qd) every two weeks.

    Drug: LPM6690176

Interventions

  • DrugLPM6690176

    Administered orally

    Also known as: LY01024

06

What researchers measure

Primary outcomes

  1. Number of dose-limiting toxicities (DLTs)

    Time frame: From the first dose of study drug treatment through Cycle 1 (28 days)

  2. maximum tolerated dose (MTD) of LPM6690176

    Time frame: From the first dose of study drug treatment through Cycle 1 (28 days)

Secondary outcomes

  1. Overall response rate (ORR)

    ORR is defined as the percentage of participants who had confirmed complete response (CR) or partial response (PR) assessed by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Time frame: Approximately 2 years

  2. Duration of response (DOR)

    DOR is defined as the time from the first determination of an objective response (CR or PR) per RECIST v1.1 until the first documentation of disease progression or death, whichever occurs first, as assessed by the investigator

    Time frame: Approximately 2 years

  3. isease control rate (DCR)

    DCR is defined as the percentage of participants with best overall response of CR, PR, or stable disease (SD) per RECIST v1.1 as assessed by the investigato

    Time frame: Approximately 2 years

  4. Progression-free survival (PFS)

    PFS is defined as the time from the date of the first dose of study drug treatment to the date of the first documentation of progressive disease or death, whichever occurs first, as assessed by the investigator using RECIST v1.1.

    Time frame: Approximately 2 years

  5. Overall survival (OS)

    OS is defined as the time from the date of the first dose of study drug treatment to the date of death (due to any reason) or documented last contact

    Time frame: Approximately 3 years

  6. Maximum plasma concentration

    Maximum plasma concentration (Cmax) of LPM6690176 and its N-demethylated metabolite after a single dose and multiple dose

    Time frame: From Pre-dose of Cycle 1 and up to Pre-dose of Cycle 2 (28 days).

  7. Time to maximum plasma concentration

    Time to maximum plasma concentration (Tmax) of LPM6690176 and its N-demethylated metabolite after a single dose and multiple dose.

    Time frame: From Pre-dose of Cycle 1 and up to Pre-dose of Cycle 2 (28 days).

  8. Area under the plasma concentration-time curve

    Area under the concentration versus time curve from time zero to the last quantifiable time point (AUClast) of LPM6690176 and its N-demethylated metabolite after a single dose and multiple dose; Area under the concentration versus time curve from time 0 extrapolated to infinite time (AUCinf) of LPM6690176 and its N-demethylated metabolite after a single dose and multiple dose.

    Time frame: From Pre-dose of Cycle 1 and up to Pre-dose of Cycle 2 (28 days).

  9. Elimination half-life

    Elimination half-life (t1/2) of LPM6690176 and its N-demethylated metabolite after a single dose and multiple dose.

    Time frame: From Pre-dose of Cycle 1 and up to Pre-dose of Cycle 2 (28 days).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Feb 2026, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2024
First posted
Feb 5, 2024
StartActual
Mar 12, 2024
Primary completionEst.
Feb 2026
CompletionEst.
Feb 2027
Last update
Mar 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06240546
Responsible party
Sponsor
First posted
Feb 5, 2024
Start date
Mar 12, 2024
Primary completion
Feb 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
Mar 15, 2024

Study contacts

Lin Shen, Doctor
Contact
doctorshenlin@sina.cn
0086-10-88121122
Lin Shen, Doctor
principal investigator · Peking University Cancer Hospital & Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion